Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge.

Domi A, Feldmann F, Basu R, McCurley N, Shifflett K, Emanuel J, Hellerstein MS, Guirakhoo F, Orlandi C, Flinko R, Lewis GK, Hanley PW, Feldmann H, Robinson HL, Marzi A.

Sci Rep. 2018 Jan 16;8(1):864. doi: 10.1038/s41598-017-19041-y.

2.

A Zika Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in a Lethal Challenge Model.

Brault AC, Domi A, McDonald EM, Talmi-Frank D, McCurley N, Basu R, Robinson HL, Hellerstein M, Duggal NK, Bowen RA, Guirakhoo F.

Sci Rep. 2017 Nov 7;7(1):14769. doi: 10.1038/s41598-017-15039-8.

3.

Differential Neurovirulence of African and Asian Genotype Zika Virus Isolates in Outbred Immunocompetent Mice.

Duggal NK, Ritter JM, McDonald EM, Romo H, Guirakhoo F, Davis BS, Chang GJ, Brault AC.

Am J Trop Med Hyg. 2017 Nov;97(5):1410-1417. doi: 10.4269/ajtmh.17-0263. Epub 2017 Aug 18.

4.

Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.

Schleiss MR, Berka U, Watson E, Aistleithner M, Kiefmann B, Mangeat B, Swanson EC, Gillis PA, Hernandez-Alvarado N, Fernández-Alarcón C, Zabeli JC, Pinschewer DD, Lilja AE, Schwendinger M, Guirakhoo F, Monath TP, Orlinger KK.

Clin Vaccine Immunol. 2017 Jan 5;24(1). pii: e00300-16. doi: 10.1128/CVI.00300-16. Print 2017 Jan.

5.

Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection.

Cardin RD, Bravo FJ, Pullum DA, Orlinger K, Watson EM, Aspoeck A, Fuhrmann G, Guirakhoo F, Monath T, Bernstein DI.

Vaccine. 2016 Apr 12;34(17):1993-9. doi: 10.1016/j.vaccine.2016.03.005. Epub 2016 Mar 10.

PMID:
26973071
6.

Development of antigen-specific memory CD8+ T cells following live-attenuated chimeric West Nile virus vaccination.

Smith HL, Monath TP, Pazoles P, Rothman AL, Casey DM, Terajima M, Ennis FA, Guirakhoo F, Green S.

J Infect Dis. 2011 Feb 15;203(4):513-22. doi: 10.1093/infdis/jiq074. Epub 2011 Jan 7.

7.

Sequential immunization with heterologous chimeric flaviviruses induces broad-spectrum cross-reactive CD8+ T cell responses.

Singh R, Rothman AL, Potts J, Guirakhoo F, Ennis FA, Green S.

J Infect Dis. 2010 Jul 15;202(2):223-33. doi: 10.1086/653486.

8.

Direct random insertion of an influenza virus immunologic determinant into the NS1 glycoprotein of a vaccine flavivirus.

Rumyantsev AA, Zhang ZX, Gao QS, Moretti N, Brown N, Kleanthous H, Delagrave S, Guirakhoo F, Collett MS, Pugachev KV.

Virology. 2010 Jan 20;396(2):329-38. doi: 10.1016/j.virol.2009.10.033. Epub 2009 Nov 12.

9.

Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.

Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J.

Vaccine. 2010 Jan 8;28(3):632-49. doi: 10.1016/j.vaccine.2009.09.098. Epub 2009 Oct 4. Review.

PMID:
19808029
10.

Evaluation of chimeric Japanese encephalitis and dengue viruses for use in diagnostic plaque reduction neutralization tests.

Johnson BW, Kosoy O, Hunsperger E, Beltran M, Delorey M, Guirakhoo F, Monath T.

Clin Vaccine Immunol. 2009 Jul;16(7):1052-9. doi: 10.1128/CVI.00095-09. Epub 2009 May 20.

11.

Safety of flavivirus chimeric vaccines: answer to Ishikawa et al. [Vaccine 26 (22) (2008) 2772-2781].

Guy B, Guirakhoo F, Watson M, Higgs S, Monath TP.

Vaccine. 2008 Aug 5;26(33):4107-8. doi: 10.1016/j.vaccine.2008.05.056. Epub 2008 Jun 9. No abstract available.

PMID:
18573573
12.

Analysis of ChimeriVax Japanese Encephalitis Virus envelope for T-cell epitopes and comparison to circulating strain sequences.

De Groot AS, Martin W, Moise L, Guirakhoo F, Monath T.

Vaccine. 2007 Nov 19;25(47):8077-84. Epub 2007 Sep 29.

PMID:
17942198
13.

Construction and biological characterization of artificial recombinants between a wild type flavivirus (Kunjin) and a live chimeric flavivirus vaccine (ChimeriVax-JE).

Pugachev KV, Schwaiger J, Brown N, Zhang ZX, Catalan J, Mitchell FS, Ocran SW, Rumyantsev AA, Khromykh AA, Monath TP, Guirakhoo F.

Vaccine. 2007 Sep 17;25(37-38):6661-71. Epub 2007 Jul 27.

PMID:
17693000
14.

A single M protein mutation affects the acid inactivation threshold and growth kinetics of a chimeric flavivirus.

Maier CC, Delagrave S, Zhang ZX, Brown N, Monath TP, Pugachev KV, Guirakhoo F.

Virology. 2007 Jun 5;362(2):468-74. Epub 2007 Feb 15.

15.

Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand.

Higgs S, Vanlandingham DL, Klingler KA, McElroy KL, McGee CE, Harrington L, Lang J, Monath TP, Guirakhoo F.

Am J Trop Med Hyg. 2006 Nov;75(5):986-93.

PMID:
17124001
16.

Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE).

Reid M, Mackenzie D, Baron A, Lehmann N, Lowry K, Aaskov J, Guirakhoo F, Monath TP.

Am J Trop Med Hyg. 2006 Oct;75(4):659-63.

PMID:
17038690
17.

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, Yoksan S, Duan X, Ermak TH, Kanesa-Thasan N, Bedford P, Lang J, Quentin-Millet MJ, Monath TP.

Hum Vaccin. 2006 Mar-Apr;2(2):60-7. Epub 2006 Mar 15.

PMID:
17012873
18.

Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax)-JE) in non-human primates.

Dean CH, Alarcon JB, Waterston AM, Draper K, Early R, Guirakhoo F, Monath TP, Mikszta JA.

Hum Vaccin. 2005 May-Jun;1(3):106-11. Epub 2005 May 9. Erratum in: Hum Vaccin. 2005 Sep-Oct;1(5):179.

PMID:
17012854
19.

A live, attenuated recombinant West Nile virus vaccine.

Monath TP, Liu J, Kanesa-Thasan N, Myers GA, Nichols R, Deary A, McCarthy K, Johnson C, Ermak T, Shin S, Arroyo J, Guirakhoo F, Kennedy JS, Ennis FA, Green S, Bedford P.

Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6694-9. Epub 2006 Apr 14. Erratum in: Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10823.

20.

New developments in flavivirus vaccines with special attention to yellow fever.

Pugachev KV, Guirakhoo F, Monath TP.

Curr Opin Infect Dis. 2005 Oct;18(5):387-94. Review.

PMID:
16148524
21.

Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys.

Monath TP, Myers GA, Beck RA, Knauber M, Scappaticci K, Pullano T, Archambault WT, Catalan J, Miller C, Zhang ZX, Shin S, Pugachev K, Draper K, Levenbook IS, Guirakhoo F.

Biologicals. 2005 Sep;33(3):131-44.

PMID:
15975826
22.

Recombination and flavivirus vaccines: a commentary.

Monath TP, Kanesa-Thasan N, Guirakhoo F, Pugachev K, Almond J, Lang J, Quentin-Millet MJ, Barrett AD, Brinton MA, Cetron MS, Barwick RS, Chambers TJ, Halstead SB, Roehrig JT, Kinney RM, Rico-Hesse R, Strauss JH.

Vaccine. 2005 Apr 27;23(23):2956-8. No abstract available.

PMID:
15811640
23.

Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells.

Brandler S, Brown N, Ermak TH, Mitchell F, Parsons M, Zhang Z, Lang J, Monath TP, Guirakhoo F.

Am J Trop Med Hyg. 2005 Jan;72(1):74-81.

PMID:
15728870
24.

Construction of yellow fever/St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic tool.

Pugachev KV, Guirakhoo F, Mitchell F, Ocran SW, Parsons M, Johnson BW, Kosoy OL, Lanciotti RS, Roehrig JT, Trent DW, Monath TP.

Am J Trop Med Hyg. 2004 Nov;71(5):639-45.

PMID:
15569798
25.

A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.

Guirakhoo F, Zhang Z, Myers G, Johnson BW, Pugachev K, Nichols R, Brown N, Levenbook I, Draper K, Cyrek S, Lang J, Fournier C, Barrere B, Delagrave S, Monath TP.

J Virol. 2004 Sep;78(18):9998-10008.

26.

Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine.

Beasley DW, Li L, Suderman MT, Guirakhoo F, Trent DW, Monath TP, Shope RE, Barrett AD.

Vaccine. 2004 Sep 9;22(27-28):3722-6.

PMID:
15315852
27.

Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.

Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K, Lang J, Ocran S, Mitchell F, Parsons M, Brown N, Brandler S, Fournier C, Barrere B, Rizvi F, Travassos A, Nichols R, Trent D, Monath T.

J Virol. 2004 May;78(9):4761-75.

28.

Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction.

Johnson BW, Chambers TV, Crabtree MB, Guirakhoo F, Monath TP, Miller BR.

Am J Trop Med Hyg. 2004 Jan;70(1):89-97.

PMID:
14971704
29.

High fidelity of yellow fever virus RNA polymerase.

Pugachev KV, Guirakhoo F, Ocran SW, Mitchell F, Parsons M, Penal C, Girakhoo S, Pougatcheva SO, Arroyo J, Trent DW, Monath TP.

J Virol. 2004 Jan;78(2):1032-8.

30.

Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.

Monath TP, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy C, Blum P, Woodward S, McCarthy K, Mathis D, Johnson C, Bedford P.

J Infect Dis. 2003 Oct 15;188(8):1213-30. Epub 2003 Oct 3.

PMID:
14551893
31.

Traditional and novel approaches to flavivirus vaccines.

Pugachev KV, Guirakhoo F, Trent DW, Monath TP.

Int J Parasitol. 2003 May;33(5-6):567-82. Review.

PMID:
12782056
32.

West Nile virus vaccine.

Monath TP, Arroyo J, Miller C, Guirakhoo F.

Curr Drug Targets Infect Disord. 2001 May;1(1):37-50. Review.

PMID:
12455232
33.

Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes.

Johnson BW, Chambers TV, Crabtree MB, Bhatt TR, Guirakhoo F, Monath TP, Miller BR.

Am J Trop Med Hyg. 2002 Sep;67(3):260-5.

PMID:
12408664
34.

Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.

Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Draper K, Monath TP.

Virology. 2002 Jun 20;298(1):146-59.

35.

Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil.

Galler R, Pugachev KV, Santos CL, Ocran SW, Jabor AV, Rodrigues SG, Marchevsky RS, Freire MS, Almeida LF, Cruz AC, Yamamura AM, Rocco IM, da Rosa ES, Souza LT, Vasconcelos PF, Guirakhoo F, Monath TP.

Virology. 2001 Nov 25;290(2):309-19.

36.

Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections.

Monath TP, McCarthy K, Bedford P, Johnson CT, Nichols R, Yoksan S, Marchesani R, Knauber M, Wells KH, Arroyo J, Guirakhoo F.

Vaccine. 2002 Jan 15;20(7-8):1004-18.

PMID:
11803060
37.

Heterogeneous nature of the genome of the ARILVAX yellow fever 17D vaccine revealed by consensus sequencing.

Pugachev KV, Ocran SW, Guirakhoo F, Furby D, Monath TP.

Vaccine. 2002 Jan 15;20(7-8):996-9.

PMID:
11803058
39.

Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.

Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Soike K, Ratterree M, Monath TP.

J Virol. 2001 Aug;75(16):7290-304.

41.

Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).

Arroyo J, Guirakhoo F, Fenner S, Zhang ZX, Monath TP, Chambers TJ.

J Virol. 2001 Jan;75(2):934-42.

42.

Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.

Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, Arroyo J, Georgakopoulos K, Catalan J, Monath TP.

J Virol. 2000 Jun;74(12):5477-85.

43.

Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.

Monath TP, Levenbook I, Soike K, Zhang ZX, Ratterree M, Draper K, Barrett AD, Nichols R, Weltzin R, Arroyo J, Guirakhoo F.

J Virol. 2000 Feb;74(4):1742-51.

45.

Effects of humanization by variable domain resurfacing on the antiviral activity of a single-chain antibody against respiratory syncytial virus.

Delagrave S, Catalan J, Sweet C, Drabik G, Henry A, Rees A, Monath TP, Guirakhoo F.

Protein Eng. 1999 Apr;12(4):357-62.

PMID:
10325407
46.

Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.

Monath TP, Soike K, Levenbook I, Zhang ZX, Arroyo J, Delagrave S, Myers G, Barrett AD, Shope RE, Ratterree M, Chambers TJ, Guirakhoo F.

Vaccine. 1999 Apr 9;17(15-16):1869-82.

PMID:
10217584
47.

Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection.

Weltzin R, Kleanthous H, Guirakhoo F, Monath TP, Lee CK.

Vaccine. 1997 Mar;15(4):370-6.

PMID:
9141207
48.
49.

Supplemental Content

Loading ...
Support Center